Destiny Pharma PLC (LSE:DEST) - Share price

Stock Report

Destiny Pharma PLC DEST

Latest Morningstar Commentary
DateAuthor Headline

Latest Company News

Previous Stories...
04/06/201914:39LSEGrant of OptionsDSH
04/06/201912:06LSEResult of AGMRAG
09/05/201914:06LSEAppointment of NOMAD and Joint BrokerAPP
29/04/201914:28LSEPosting of Annual Report and Notice of AGMMSC
09/04/201907:00LSEFinal ResultsFR
05/04/201917:06LSEExercise of OptionsIOE
01/04/201915:03LSEExercise of OptionsIOE
28/03/201918:13LSEExercise of OptionsIOE
27/03/201907:00LSEMedPharm to develop new XF-drug formulationsNRA
22/03/201909:47LSENotice of ResultsNOR
06/03/201918:00LSEExercise of OptionsIOE
28/01/201907:00LSESecond positive phase 1 trial data for XF-73MSC
25/01/201907:00LSENew grant awarded under UK-China AMR programmeMSC
24/01/201911:50LSEDestiny Pharma notes UK 5-year action plan on AMRNRA
01/11/201807:00LSEResearch collaboration with Southampton UniversityNRA
25/10/201816:05LSEGrant of OptionsDSH
25/10/201807:00LSEDirectorate ChangeBOA
24/10/201807:00LSEUK government highlights global threat of AMRNRA
19/10/201807:00LSEBIA celebrates UK bioscience innovativeNRA
26/09/201807:00LSEDr Jesús González appointed Chief Medical OfficerMSC
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2019 Morningstar. All rights reserved.